Dopo l'orario di chiusura: 3.13

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc Borsa (APRE) Ultime notizie

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc Borsa (APRE) Ultime notizie

APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com Australia

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha

APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com

APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com Canada

APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com UK

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review (APLT) - Seeking Alpha

Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug - Benzinga

Applied Therapeutics Shares Rise as Drug Continues with Priority Review - MarketWatch

Ascendis Pharma price target raised to $289 from $264 at Wells Fargo - TipRanks

Aprea Therapeutics to Present at H.C. Wainwright Investment Conference - MSN

Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 - GlobeNewswire

Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 - Yahoo Finance

UPDATE – Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference - ForexTV.com

Doylestown Cancer Pharma Moves Closer to Starting Clinical Testing on Its 3rd Experimental Cancer Treatment - BUCKSCO.Today

APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com India

APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com Canada

APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com UK

APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com

Aprea Therapeutics to Present at H.C. Wainwright Investment Conference - MyChesCo

Myelodysplastic Syndrome (MDS) Drugs Market Research Report Explores 2024-2033 | Size, Growth, Demand, Trends - WhaTech

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference - ForexTV.com

Larimar Therapeutics Engages with Investors at Key Conferences - MyChesCo

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 41.3% in July - Defense World

Biora Therapeutics, Inc. (NASDAQ:BIOR) Forecasted to Post Q3 2024 Earnings of ($0.42) Per Share - Defense World

Q3 2024 Earnings Estimate for Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Issued By HC Wainwright - Defense World

Q3 2024 EPS Estimates for Astria Therapeutics, Inc. Decreased by HC Wainwright (NASDAQ:ATXS) - Defense World

Wedbush Comments on Aerovate Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:AVTE) - Defense World

Aprea Therapeutics (NASDAQ:APRE) Releases Earnings Results, Beats Estimates By $0.05 EPS - Defense World

Aprea Therapeutics’ (APRE) Outperform Rating Reaffirmed at Wedbush - Defense World

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Progress in Clinical Trials - MyChesCo

Aprea Therapeutics (NASDAQ:APRE) Given “Buy” Rating at HC Wainwright - Defense World

APRE stock touches 52-week low at $3.22 amid market challenges - Investing.com Canada

APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace

APRE stock touches 52-week low at $3.22 amid market challenges - Investing.com

Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates - MSN

APRE stock touches 52-week low at $3.22 amid market challenges - Investing.com UK

Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - wallstreet:online

Aclaris Therapeutics Reports Q2 2024 Financial Results and Updates - MyChesCo

Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans? - Simply Wall St

Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Decline in Short Interest - Defense World

Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely? - Yahoo Finance

Alltrna Announces Updates to Its Board of Directors - Financial Times

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 13.3% in June - Defense World

Small-Cap Sunday Highlights: Andean Precious Metals, Aadi Bioscience, Aprea Therapeutics, Arc Document Solutions, Curaleaf - The Dales Report

DDR Defective Tumors Industry is Expected to Reach Rapid Growth - openPR

Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Drop in Short Interest - Defense World

Savara Inc. Announces Breakthrough in aPAP Treatment with IMPALA-2 Trial Success - MyChesCo

FY2026 EPS Estimates for Aprea Therapeutics, Inc. Increased by Analyst (NASDAQ:APRE) - Defense World

Aprea Therapeutics (NASDAQ:APRE) Receives “Buy” Rating from HC Wainwright - Defense World

Aprea Therapeutics Hosts Virtual Event on Promising Cancer Therapy - MyChesCo

Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug - MSN

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 - ForexTV.com

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 - GlobeNewswire Inc.

Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug - MyChesCo

Aprea Therapeutics (NASDAQ:APRE) Given Buy Rating at HC Wainwright - Defense World

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor - EIN News

Amplitude, Inc. (NASDAQ:AMPL) Short Interest Up 34.5% in May - Defense World

Simile a APRE